Moreover, certain exogenous drugs like empagliflozin have demonstrated the ability to activate the AMPK/glycogen synthase kinase 3 beta (GSK3β) signaling pathway in diabetic cardiomyopathy. This evidence concerns the gene GSK3B and diabetic cardiomyopathy.